Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Regulatory News & FDA Approvals » Roche Nabs CE Mark for PIK3CA Test for Breast Cancer

Roche Nabs CE Mark for PIK3CA Test for Breast Cancer

Dec 15, 2020
|
staff reporter

NEW YORK – Roche announced Tuesday it has received CE marking for its Cobas PIK3CA Mutation test for identifying patients with metastatic breast cancer who might benefit the most from phosphoinositide 3-kinase (PI3K) targeted therapy. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Breathe It Out

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

The Next Batch

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Switch for the Second

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.

Science Reviews How Non-Genetic DNA Features Expand Utility of Liquid Biopsies, Presents Study of Enzymes in DNA Methylation

In Science this week: review discusses advances in liquid biopsies, and more.

What's Popular?

In Regulatory News & FDA Approvals

  1. CLIA Waiver in Hand, Binx Health Targeting Retailers, Urgent Care Centers With STI Tests

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.